News | May 30, 2024
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
The award recognizes powerful science–industry collaborations for social good
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
